Page 66 - ITPS-7-3

INNOSC Theranostics and
Pharmacological Sciences Designing miRNA ONTs for cardiometabolic pandemics

Trafficking, sorting, and function. Genomics Proteomics Cells. 2021;10(11):3097.
Bioinformatics. 2015;13(1):17-24.
doi: 10.3390/cells10113097
doi: 10.1016/j.gpb.2015.02.001
36. Smith ES, Whitty E, Yoo B, Moore A, Sempere LF,
25. Assmann TS, Milagro FI, Martinez JA. Crosstalk Medarova Z. Clinical Applications of Short Non-Coding
between microRNAs, the putative target genes and RNA-Based Therapies in the Era of Precision Medicine.
the lncRNA network in metabolic diseases. Mol Med Cancers (Basel). 2022;14(6):1588.
Rep. 2019;20(4):3543-3554.
doi: 10.3390/cancers14061588
doi: 10.3892/mmr.2019.10595
37. Bajan S, Hutvagner G. RNA-based therapeutics: From
26. Bennett CF, Kordasiewicz HB, Cleveland DW. Antisense antisense oligonucleotides to miRNAs. Cells. 2020;9(1):137.
drugs make sense for neurological diseases. Annu Rev doi: 10.3390/cells9010137
Pharmacol Toxicol. 2021;61:831-852.
38. Weidner J, Kolosionek E, Holmila R, et al. Gymnotic
doi: 10.1146/annurev-pharmtox-010919-023738
uptake of AntimiRs alter microRNA-34a levels in 2D
27. Garofalo M, Condorelli G, Croce CM. MicroRNAs and 3D epithelial cell culture. Mol Ther Nucleic Acids.
in diseases and drug response. Curr Opin Pharmacol. 2023;33:898-907.
2008;8:661-667.
doi: 10.1016/j.omtn.2023.08.014
doi: 10.1016/j.coph.2008.06.005
39. Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G,
28. Jae N, Dimmeler S. Noncoding RNAs in vascular diseases. Amero P, Rodriguez-Aguayo C. Targeting miRNAs and
Circ Res. 2020;126(9):1127-1145. other non-coding RNAs as a therapeutic approach: An
update. Noncoding RNA. 2023;9(2):27.
doi: 10.1161/CIRCRESAHA.119.315938
doi: 10.3390/ncrna9020027
29. Chandan K, Gupta M, Sarwat M. Role of host and pathogen-
derived MicroRNAs in immune regulation during infectious 40. Kilikevicius A, Meister G, Corey DR. Reexamining
and inflammatory diseases. Front Immunol. 2019;10:3081. assumptions about miRNA-guided gene silencing. Nucleic
Acids Res. 2022;50(2):617-634.
doi: 10.3389/fimmu.2019.03081
doi: 10.1093/nar/gkab1256
30. Benavides-Aguilar JA, Torres-Copado A, Isidoro-Sanchez J,
et al. The regulatory role of MicroRNAs in obesity and obesity- 41. Roberts TC, Langer R, Wood MJA. Advances in
derived ailments. Genes (Basel). 2023;14(11):2070. oligonucleotide drug delivery. Nat Rev Drug Discov.
2020;19(10):673-694.
doi: 10.3390/genes14112070
doi: 10.1038/s41573-020-0075-7
31. Shah V, Shah J. Recent trends in targeting miRNAs for
cancer therapy. J Pharm Pharmacol. 2020;72(12):1732-1749. 42. Kim T, Croce CM. MicroRNA: Trends in clinical trials of
cancer diagnosis and therapy strategies. Exp Mol Med.
doi: 10.1111/jphp.13351
2023;55(7):1314-1321.
32. Kousar K, Ahmad T, Abduh MS, et al. miRNAs in regulation
of tumor microenvironment, chemotherapy resistance, doi: 10.1038/s12276-023-01050-9
immunotherapy modulation and miRNA therapeutics in 43. Traber GM, Yu AM. RNAi-based therapeutics and novel
cancer. Int J Mol Sci. 2022;23(22):13822. RNA bioengineering technologies. J Pharmacol Exp Ther.
2023;384(1):133-154.
doi: 10.3390/ijms232213822
doi: 10.1124/jpet.122.001234
33. Veiga RN, Zambalde EP, Cox L, et al. Regulation of
immune cells by microRNAs and microRNA-based cancer 44. Corydon IJ, Fabian-Jessing BK, Jakobsen TS, et al. 25 years
immunotherapy. Adv Exp Med Biol. 2022;1385:75-108. of maturation: A systematic review of RNAi in the clinic.
Mol Ther Nucleic Acids. 2023;33:469-482.
doi: 10.1007/978-3-031-08356-3_3
doi: 10.1016/j.omtn.2023.07.018
34. Otmani K, Rouas R, Lewalle P. OncomiRs as noncoding
RNAs having functions in cancer: Their role in immune 45. Baumann V, Winkler J. miRNA-based therapies:
suppression and clinical implications. Front Immunol. Strategies and delivery platforms for oligonucleotide
2022;13:913951. and non-oligonucleotide agents. Future Med Chem.
2014;6(17):1967-1984.
doi: 10.3389/fimmu.2022.913951
doi: 10.4155/fmc.14.116
35. Momin MY, Gaddam RR, Kravitz M, Gupta A, Vikram A.
The challenges and opportunities in the development of 46. Zhang MM, Bahal R, Rasmussen TP, Manautou JE, Zhong XB.
MicroRNA therapeutics: A multidisciplinary viewpoint. The growth of siRNA-based therapeutics: Updated clinical

Volume 7 Issue 3 (2024) 13 doi: 10.36922/itps.3025